Chronic myeloid leukemia (CML) is caused by BCRABL1 in a cell with the biological
potential, intrinsic or acquired, to cause leukemia. This cell is commonly termed the CML …

The E2F family of transcription factors (E2Fs) consist of eight genes in mammals. These
genes encode ten proteins that are usually classified as transcriptional activators or …

Deregulated oxidative metabolism is a hallmark of leukaemia. While tyrosine kinase
inhibitors (TKIs) such as imatinib have increased survival of chronic myeloid leukaemia …

Whilst it is recognised that targeting self-renewal is an effective way to functionally impair the
quiescent leukaemic stem cells (LSC) that persist as residual disease in chronic myeloid …

Drug tolerant/resistant leukemic stem cell (LSC) subpopulations may explain frequent
relapses in acute myeloid leukemia (AML), suggesting that these relapse-initiating cells …

Targeted therapies against the BCR-ABL1 kinase have revolutionized treatment of chronic
phase (CP) chronic myeloid leukemia (CML). In contrast, management of blast crisis (BC) …

Biological therapies have changed the face of oncology by targeting cancerous cells while
reducing the effect on normal tissue. This publication focuses mainly on new therapies that …

Many long noncoding RNAs (lncRNAs) have been annotated, but their functions remain
unknown. The authors found a novel lnc‐APUE (lnc RNA a ccelerating p roliferation by u …

The transcription factor E2F, the principal target of the tumor suppressor pRB, plays crucial
roles in cell proliferation and tumor suppression. In almost all cancers, pRB function is …

Acute myeloid leukemia (AML) is an aggressive hematopoietic malignancy for which there is
an unmet need for novel treatment strategies. Here, we characterize the growth arrest and …